Profile data is unavailable for this security.
About the company
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.80m
- Incorporated2021
- Employees5.00
- LocationGenflow Biosciences PLC6 Heddon StreetLONDON W1B 4BTUnited KingdomGBR
- Websitehttps://genflowbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ValiRx Plc | 49.78k | -1.78m | 2.45m | 14.00 | -- | 0.3579 | -- | 49.24 | -0.0094 | -0.0094 | 0.0002 | 0.0092 | 0.0147 | 0.00 | 0.6068 | 3,555.71 | -55.35 | -48.98 | -51.45 | -49.62 | 100.00 | -- | -3,775.95 | -16,086.59 | 8.87 | -- | 0.0022 | -- | 418.54 | -- | 5.99 | -- | -37.39 | -- |
| TheraCryf PLC | 0.00 | -2.01m | 4.51m | 9.00 | -- | 0.9398 | -- | -- | -0.0017 | -0.0017 | 0.00 | 0.0022 | 0.00 | -- | -- | 0.00 | -41.20 | -38.70 | -53.79 | -42.97 | -- | -- | -- | -1,407.46 | -- | -- | 0.00 | -- | -100.00 | -- | 38.13 | -- | -- | -- |
| N4 Pharma PLC | 7.07k | -1.07m | 4.99m | 4.00 | -- | 2.83 | -- | 706.32 | -0.0025 | -0.0025 | 0.00002 | 0.0021 | 0.0045 | -- | 0.0756 | 1,767.50 | -71.04 | -59.59 | -74.91 | -63.90 | -- | -- | -15,981.33 | -67,987.22 | -- | -- | 0.00 | -- | 273.33 | -- | 16.60 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 5.35m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 6.56m | 5.00 | -- | 0.779 | 468.54 | 5.70 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| Talisman Metals PLC | 0.00 | 65.71k | 6.59m | 1.00 | -- | 2.73 | 100.23 | -- | -0.0065 | -0.0161 | 0.00 | 0.0376 | 0.00 | -- | -- | 0.00 | 3.15 | -30.40 | 3.64 | -33.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 99.94 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 6.89m | 12.00 | -- | 1.18 | -- | 0.8691 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| IXICO PLC | 6.53m | -1.65m | 7.07m | 79.00 | -- | 0.602 | -- | 1.08 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 9.87m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 17.02m | -- | -- | 2.13 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 17.50m | 24.00 | -- | 21.92 | -- | 10.97 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 20.71m | 5.00 | -- | 8.85 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 20.73m | 41.00 | -- | 2.20 | -- | 4.47 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 09 Jan 2025 | 15.15m | 3.07% |
